These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 7046899)
41. Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group. Coltman CA; Luce JK; McKelvey EM; Jones SE; Moon TE Cancer Treat Rep; 1977 Sep; 61(6):1067-78. PubMed ID: 71206 [TBL] [Abstract][Full Text] [Related]
42. BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. Durant JR; Gams RA; Bartolucci AA; Dorfman RF Cancer Treat Rep; 1977 Sep; 61(6):1085-96. PubMed ID: 332345 [TBL] [Abstract][Full Text] [Related]
43. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771 [TBL] [Abstract][Full Text] [Related]
44. The place of radiation therapy in the treatment of non-Hodgkin's lymphomas. Hellman S; Chaffey JT; Rosenthal DS; Moloney WC; Canellos GP; Skarin AT Cancer; 1977 Feb; 39(2 Suppl):843-51. PubMed ID: 65208 [TBL] [Abstract][Full Text] [Related]
45. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Elias L; Portlock CS; Rosenberg SA Cancer; 1978 Oct; 42(4):1705-10. PubMed ID: 361209 [TBL] [Abstract][Full Text] [Related]
46. Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens. Cabanillas F; Rodriguez V; Freireich EJ Med Pediatr Oncol; 1978; 4(4):321-31. PubMed ID: 364284 [TBL] [Abstract][Full Text] [Related]
47. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329 [TBL] [Abstract][Full Text] [Related]
48. [Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report]. Sampi K; Honda T; Hattori M Gan To Kagaku Ryoho; 1984 May; 11(5):1012-7. PubMed ID: 6202245 [TBL] [Abstract][Full Text] [Related]
49. High grade nonHodgkin's lymphoma: management with moderate dose combination chemotherapy. Palmer MC; Fitzharris BM; Robinson BA; Atkinson CH; Colls BM N Z Med J; 1988 May; 101(846):255-8. PubMed ID: 3374896 [TBL] [Abstract][Full Text] [Related]
50. Advances in chemotherapy for large cell lymphoma. Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781 [TBL] [Abstract][Full Text] [Related]
51. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology. Canellos GP; Skarin AT; Rosenthal DS; Moloney WC; Frei E Cancer Treat Rep; 1981; 65 Suppl 1():125-9. PubMed ID: 6173118 [TBL] [Abstract][Full Text] [Related]
52. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Laver JH; Mahmoud H; Pick TE; Hutchison RE; Weinstein HJ; Schwenn M; Weitzman S; Murphy SB; Ochoa S; Shuster JJ Leuk Lymphoma; 2002 Jan; 43(1):105-9. PubMed ID: 11908712 [TBL] [Abstract][Full Text] [Related]
53. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
54. [A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result]. Kimura I; Ohnoshi T; Masaoka T; Sampi K; Namba K Gan To Kagaku Ryoho; 1986 Sep; 13(9):2813-9. PubMed ID: 3530138 [TBL] [Abstract][Full Text] [Related]
55. Chemotherapy of the non-Hodgkin's lymphomas: the Stanford experience. Portlock CS; Rosenberg SA Cancer Treat Rep; 1977 Sep; 61(6):1049-55. PubMed ID: 332344 [No Abstract] [Full Text] [Related]
57. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. Hagenbeek A; Eghbali H; Monfardini S; Vitolo U; Hoskin PJ; de Wolf-Peeters C; MacLennan K; Staab-Renner E; Kalmus J; Schott A; Teodorovic I; Negrouk A; van Glabbeke M; Marcus R J Clin Oncol; 2006 Apr; 24(10):1590-6. PubMed ID: 16575010 [TBL] [Abstract][Full Text] [Related]
58. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma. Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783 [TBL] [Abstract][Full Text] [Related]
59. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127 [TBL] [Abstract][Full Text] [Related]
60. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas. Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]